154 related articles for article (PubMed ID: 16649978)
1. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia.
Sonmez A; Dogru T; Tasci I; Yilmaz MI; Pinar M; Naharci I; Bingol N; Kilic S; Demirtas A; Bingol S; Ozgurtas T; Erikci S
Clin Endocrinol (Oxf); 2006 May; 64(5):567-72. PubMed ID: 16649978
[TBL] [Abstract][Full Text] [Related]
2. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
3. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
5. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
6. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
7. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
8. Relationship between adiponectin and metabolic variables in Caribbean offspring of patients with type 2 diabetes mellitus.
Ezenwaka CE; Kalloo R; Uhlig M; Eckel J
Horm Metab Res; 2004 Apr; 36(4):238-42. PubMed ID: 15114523
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. [Plasma levels of adiponectin and tumor necrosis factor-alpha in children with obesity].
Yan WJ; Wu J; Mo J; Huang CW; Peng LW; Xu L
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):47-50. PubMed ID: 19149923
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia.
Inoue M; Yano M; Yamakado M; Maehata E; Suzuki S
Metabolism; 2006 Sep; 55(9):1248-54. PubMed ID: 16919546
[TBL] [Abstract][Full Text] [Related]
12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients.
Taniguchi A; Fukushima M; Ohya M; Nakai Y; Yoshii S; Nagasaka S; Matsumoto K; Taki Y; Kuroe A; Nishimura F; Seino Y
Metabolism; 2006 Feb; 55(2):258-62. PubMed ID: 16423635
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.
Gannagé-Yared MH; Azar RR; Amm-Azar M; Khalifé S; Germanos-Haddad M; Neemtallah R; Halaby G
Metabolism; 2005 Jul; 54(7):947-51. PubMed ID: 15988706
[TBL] [Abstract][Full Text] [Related]
15. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
[TBL] [Abstract][Full Text] [Related]
16. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
[TBL] [Abstract][Full Text] [Related]
17. Does birthweight predict adolescent adiponectin levels?
Kim CS; Park JS; Park J; Nam JS; Kang ES; Ahn CW; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB; Kim DJ
Clin Endocrinol (Oxf); 2006 Feb; 64(2):162-8. PubMed ID: 16430715
[TBL] [Abstract][Full Text] [Related]
18. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
19. Treatment of dyslipidaemias with fluvastatin.
Peters TK
Br J Clin Pract Suppl; 1994 Dec; (77):16-9. PubMed ID: 19514133
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
